10 employees
PanCryos develops a next generation stem cell derived allogenic cell therapy or Type 1 diabetes.
2014
$84K
from 1 investors over 1 rounds
PanCryos raised $84K on August 1, 2018
Investors: Executive Agency for Small and Medium-sized Enterprises (EASME)